Citation Tools

Download PDFPDF

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness

Download to a citation manager

Cite this article as:
Raftery J, Clegg A, Jones J, et al
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness